ERBB2 and breast cancer: Similar results were obtained when we used fluorescently labeled trastuzumab to detect native HER2 in BT-474 breast cancer cells (Figure 3A): by far the highest fraction of clustered HER2 was observed for the tetravalent meditope (Figure 3D).